磺胺喹恶啉钠 | 967-80-6

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 抗真菌类药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 磺胺喹恶啉钠
• 中文别名: 磺胺喹噁啉钠；磺胺喹噁啉钠N；N-2-喹喔啉基-4-氨基苯磺酰胺钠盐；磺胺喹啉钠
• 英文名称: sodium 4-amino-N-(quinoxalin-2-yl)benzene-1-sulfonamide
• CAS: 967-80-6
• 化学式: C14H12N4NaO2S
• 分子量: 323.33
• InChiKey: UBDSWJJGFQSVLE-UHFFFAOYSA-N

物化性质

• 熔点：
  >296oC (dec.)
• 溶解度：
  H2O：50 mg/mL，透明至几乎透明，深黄色

计算性质

• 辛醇/水分配系数(LogP)：
  1.63
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S22,S36/37,S45
• 危险类别码：
  R22,R42/43
• WGK Germany：
  3
• 危险品运输编号：
  NONH for all modes of transport
• 海关编码：
  2935009090
• 危险标志：
  GHS07
• 危险性描述：
  H302,H317
• 危险性防范说明：
  P280

制备方法与用途

生物活性

Sulfaquinoxaline sodium（N'1-喹啉-2-基磺酰胺钠盐，SQ-Na）是sulfaquinoxaline的钠盐形式，通过抑制微生物核酸和蛋白质的合成，用于治疗家禽、猪和羊的球虫病。

靶点

细菌与寄生虫

体内研究

Sulfaquinoxaline sodium 盐在停药后两天内，在药物最大残留限量（MRL）为100 μg/kg 的浓度下，仍能检测到所有抗菌残留物。

用途

磺胺类药物，用于治疗禽球虫病。

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Cholera organisms, vaccines and preparation thereof
  申请人：Council of Scientific and Industrial Research

  公开号：EP0928831A1

  公开（公告）日：1999-07-14

  A process for the isolation of nontoxinogenic V. cholerae strain and a process for preparing a cholera vaccine from said V. cholerae strain, said process comprising (a) isolating V. cholerae from the stool of a patient suffering from cholera by spreading the stool on a selector medium specific for V. cholerae, (b) separating the non-toxinogenic V. cholerae strain from the population of the V. cholerae strains isolated in step (a), the strain having been deposited at Microbial Type Culture Collection (MTCC) at the Institute of Microbial Technology (IMT), Chandigarh, India, a constituent laboratory of the applicants and having the Accession no. MTCC B0010 which has also been deposited at American Type Culture Collection, Rockville, Maryland, USA and having Accession no. ATCC 202010, and (c) incorporating immunogenic cholera toxin (ctx) B subunit gene into the chromosome of the strain having the Accession no. MTCC B0010 (ATCC 202010) by conventional methods to produce the vaccine.

  一种分离非致毒霍乱弧菌菌株的工艺和一种从所述霍乱弧菌菌株中制备霍乱疫苗的工艺，所述工艺包括(a)通过将霍乱弧菌特异性选择培养基上的霍乱弧菌粪便分离霍乱弧菌，(b)将非致毒霍乱弧菌菌株从步骤(a)中分离的霍乱弧菌菌株群中分离出来。(b) 从步骤(a)中分离出的霍乱弧菌菌株群中分离出非致毒霍乱弧菌菌株，该菌株已存放在申请人的组成实验室印度昌迪加尔微生物技术研究所（IMT）的微生物类型培养物保藏中心（MTCC），其登录号为 MTCC B0010。MTCC B0010 也已存放在美国马里兰州罗克维尔的美国模式培养物保藏中心（American Type Culture Collection, Rockville, Maryland, USA），其登录号为 ATCC 202010。ATCC 202010，以及 (c) 将免疫原性霍乱毒素（ctx）B 亚基基因加入菌株染色体中，该菌株的登录号为 MTCC B0010（ATCC 202010）。MTCC B0010（ATCC 202010）的染色体中，以常规方法生产疫苗。
• Hedgehog pathway antagonists to treat cancer
  申请人：The Johns Hopkins University

  公开号：EP2404602A1

  公开（公告）日：2012-01-11

  The present invention relates to itraconazole or a pharmaceutically acceptable salt thereof for use in inhibiting hedgehog pathway activity related to cancer in a subject.

  本发明涉及伊曲康唑或其药学上可接受的盐，用于抑制受试者体内与癌症有关的刺猬通路活性。
• NOVEL METHODS FOR RAPID DRUG SUSCEPTIBILITY TESTING AND DRUG SCREENS FOR GROWING AND NON-GROWING CELLS OF PROKARYOTIC AND EUKARYOTIC ORIGIN
  申请人：Zhang, Ying

  公开号：EP3321371A1

  公开（公告）日：2018-05-16

  The presently disclosed subject matter provides methods, compositions, and kits for extremely rapid assessment of drug susceptibility of growing as well as non-growing cells of prokaryotic and also eukaryotic origins, without the need for organism growth, which is in contrast to the current growth-dependent methods.This growth-independent new methodology achieves extremely rapid drug susceptibility testing results previously not possible. Methods for rapidly identifying compounds with inhibitory activity against both growing and non-growing cells in real-time continuous manner with previously unachievable efficiency in drug screens using the novel methodology are also provided. Cell cultures are incubated with a drug or test agent and with a staining mixture containing a first fluorescent dye indicative the emission of which is indicative of live cells (e.g. SYBR Green I) and a second fluorescent dye indicative emitting a different color, the emission of which is indicative of dead cells (e.g. Propidium iodide). The ratio of the intensities of the emitted fluorescence of the dyes is indicative of the percentage live and dead cells in the culture.

  与目前依赖生长的方法相比，本公开的主题提供了无需生物体生长即可对原核和真核的生长和非生长细胞的药物敏感性进行极快速评估的方法、组合物和试剂盒，这种不依赖生长的新方法实现了以前无法实现的极快速药物敏感性测试结果。此外，还提供了实时连续地快速鉴定对生长细胞和非生长细胞具有抑制活性的化合物的方法，这种方法在使用新方法进行药物筛选时具有以前无法实现的效率。细胞培养物与药物或测试剂以及染色混合物一起孵育，染色混合物含有第一种荧光染料指示剂，其发射的荧光指示剂可指示活细胞（如 SYBR 绿 I）和第二种发出不同颜色的荧光染料指示剂，其发射的荧光指示剂可指示死细胞（如碘化丙啶）。染料发射荧光强度的比值表示培养液中活细胞和死细胞的百分比。
• APPLICATION OF AND PREPARATION METHOD FOR CATIONIC POLYMER MODIFIED BY FLUORINE-CONTAINING COMPOUND AS DRUG CARRIER
  申请人：Soochow University

  公开号：EP4095162A1

  公开（公告）日：2022-11-30

  The invention provides a fluorinated chitosan derivative as a drug carrier, which has the following structure: a fluorine-containing compound covalently attached to the backbone of chitosan. The chitosan has a molecular weight in the range of 1000-5000000, a degree of deacetylation of not less than 55%, and a viscosity in the range of 25-1000 cps. The fluorine-containing compound is a fluorine-containing aliphatic chain shown by the following chemical formula (I) or an aromatic ring with functional groups shown by the following formula (II) wherein Ri is halogen (fluorine, chlorine, bromine, iodine), or a halogen-substituted alkane, cycloalkane, aldehyde group, carboxyl group, alkenyl group, alkynyl group, hydroxyl group, sulfonyl chloride, sulfonic acid bond or mercapto group, for interacting with a primary amino group. The compounds of the present invention can be universally bound to a variety of drugs to promote drug absorption and bioavailability, and reduce toxicity.

  本发明提供了一种作为药物载体的氟化壳聚糖衍生物，其结构如下：一种含氟化合物共价连接到壳聚糖的骨架上。壳聚糖的分子量在 1000-5000000 之间，脱乙酰度不低于 55%，粘度在 25-1000 cps 之间。含氟化合物是由以下化学式（I）表示的含氟脂肪族链 或带有下式（II）所示官能团的芳香环 其中 Ri 为卤素（氟、氯、溴、碘），或卤素取代的烷基、环烷基、醛基、羧基、 烯基、炔基、羟基、磺酰氯、磺酸键或巯基，用于与伯氨基相互作用。本发明的化合物可与多种药物普遍结合，以促进药物的吸收和生物利用度，并降低毒性。